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Abstract 
Background: Several attempts to improve immune function in young children have been made and encouraging 
results have been collected with pidotimod (PDT), a synthetic dipeptide molecule that seems to have immunomodu-
latory activity on both innate and adaptive responses. Until now, the effects of PDT on the immune system have 
only been studied in vivo after long-term administration to evaluate whether its immunomodulatory activity might 
prevent the development of infections. This study was planned to evaluate the immunomodulatory activity of PDT 
administered together with standard antibiotic therapy in children hospitalized for community-acquired pneumonia 
(CAP).
Methods: A total of 20 children hospitalized for community-acquired pneumonia (CAP) were randomized at a 1:1 
ratio to receive either standard antibiotics plus pidotimod (PDT) or standard antibiotics alone to evaluate the immu-
nomodulatory activity of PDT. Blood samples for the evaluation of immunological parameters were drawn at the time 
of recruitment (T0) (i.e., before therapy administration), at T3 and T5 (i.e., 3 and 5 days after the initiation of therapy) as 
well as at T21 (i.e., 7 days after the therapy ended).
Results: Following pneumococcal polysaccharide stimulation, the percentage of dendritic cells (DCs) expressing 
activation and costimulatory molecules was significantly higher in children receiving PDT plus antibiotics than in the 
controls. A significant increase in tumor necrosis factor-α and/or interleukin-12 secretion and expression of toll like 
receptor 2 was observed in PDT-treated children compared with controls; this was followed by an increased release of 
proinflammatory cytokines by monocytes. In the PDT-treated group, mRNA expression of antimicrobial peptides and 
genes involved in the inflammatory response were also augmented in comparison with the controls.
Conclusions: These results demonstrate, for the first time, that PDT administered together with standard antibiotics 
is associated with a favorable persistent immunomodulatory effect in children with CAP.
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Background
In the first years of life, recurrent respiratory tract infec-
tions (RRTIs) commonly occur in otherwise healthy chil-
dren due to an increased risk of exposure to infectious 
agents coupled with the immaturity of the immune sys-
tem [1, 2]. Both innate and adaptive immunity develop 
gradually, and some aspects are not fully functional until 
5–7 years of age [3]. In comparison with adults, younger 
children have lower concentrations in their respiratory 
mucus of several proteins that exert antibacterial activ-
ity (e.g., defensins, lysozyme, IgA) as well as proteins that 
have immunomodulatory (e.g., secretoglobins, cytokines) 
and protective (e.g., trefoil proteins, heregulin) functions 
[4–8]. Moreover, a lower expression of toll-like receptors 
(TLRs) on epithelial cell membranes has been reported, 
and this leads to less efficient recognition of pathogens 
and a delayed and less effective induction of the innate 
immune response [9, 10]. On the other hand, the activity 
of lymphocytes, macrophages, and dendritic cells is poor 
in the first years of life and tends to reach adult efficiency 
only after repeated exposure to infectious agents. The 
secretion of pro-inflammatory cytokines and chemokines 
is low for the first years of life, as is the production of 
serum and mucosal antibodies [11–14].
Several attempts to improve immune function in 
young children have been made using alternative medi-
cines (e.g., plant preparations), dietary supplements 
(e.g., vitamins C and D, zinc, cod liver oil and poly-
unsaturated fatty acids), and other preparations such 
as inosine pranobex, probiotics, bacterial lysates and 
pidotimod (PDT) [15–17]. In only a few cases, scientific 
evidence of positive effects was found. However, encour-
aging results have been collected with PDT, a synthetic 
dipeptide molecule (3-l-pyroglutamyl-l-thiazolidine-
4carboxilic acid) that seems to have immunomodulatory 
activity on both innate and adaptive responses. Higher 
expression of TLR2 proteins, induction of dendritic cell 
maturation accompanied by an increased release of pro-
inflammatory molecules, upregulation of the expression 
of HLA-DR, stimulation of T lymphocyte proliferation 
and differentiation toward a Th1 phenotype, inhibition 
of thymocyte cell death and promotion of phagocytosis 
have all been demonstrated in in  vitro studies in both 
animal and human subjects [18–20]. Moreover, in  vivo 
studies have demonstrated that long-term prophylac-
tic use of PDT can be of benefit in children with RRTIs, 
reducing the total number of new infectious episodes and 
the consequent use of drugs, including antibiotics [21]. A 
recent Italian study showed that PDT treatment 400 mg/
day for 2  months was able of significantly reducing the 
number of children with upper and lower airways symp-
toms, and medications use, increasing school attend-
ance, and reducing pediatric visits for RRTIs [22]. Finally, 
it was found that in subjects with Down syndrome, the 
response to the influenza vaccine administered at the 
beginning of a 90 day-PDT course was different from the 
response in untreated children, suggesting a preferential 
activation of effector mechanisms and a potential benefi-
cial effect of immunization [23].
Until now, the effects of PDT on the immune system 
have only been studied in  vivo after long-term admin-
istration to evaluate whether its immunomodulatory 
activity might prevent the development of infections. No 
data are available on the immunological impact of PDT 
when given during an acute disease. Information regard-
ing this could be useful to understand whether this drug 
could positively influence the clinical course of an acute 
infection. This study was planned to evaluate the immu-
nomodulatory activity of PDT administered together 
with standard antibiotic therapy in children hospitalized 
for community-acquired pneumonia (CAP).
Methods
Study design
This study was carried out at the Pediatric Highly Inten-
sive Care Unit of the University of Milan, Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, 
Italy between November 1, 2013 and April 30, 2014. It 
was approved by the Ethics Committee of the Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, 
Italy. Written informed consent was obtained from the 
parents or legal guardians of all study participants, and in 
the case of patients aged ≥7 years, written consent from 
the children was also collected.
Only otherwise healthy children aged 3–14 years with 
clinical signs such as tachypnea and abnormal breath 
sounds and a chest radiograph consistent with non-
complicated CAP were considered eligible for the study. 
Complicated CAP was defined as the presence in a chest 
radiograph of more than one of the following conditions: 
parapneumonic effusion, defined as loculated pleural 
fluid; any pleural fluid parameters consistent with empy-
ema; atelectasis; and necrotizing pneumonia [24, 25]. The 
CAP diagnoses were all confirmed by chest radiographs 
evaluated by an independent expert radiologist who 
classified the findings as alveolar pneumonia, nonalveo-
lar pneumonia or no pneumonia in accordance with the 
World Health Organization criteria for the standardized 
interpretation of pediatric chest radiographs for the diag-
nosis of pneumonia [26].
Upon enrollment, detailed information regarding chil-
dren’s demographics, clinical history and the character-
istics of the disease were collected together with a blood 
sample for the evaluation of laboratory variables, includ-
ing white blood cell (WBC) counts, C-reactive protein 
(CRP) and procalcitonin (PCT) levels. A portion of the 
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blood sample obtained at the time of recruitment (T0) 
(i.e., before therapy administration) was also used for the 
immunological analyses described below. The enrolled 
children were randomly assigned in a 1:1 ratio and 
according to a computer-generated list to receive either 
standard antibiotic therapy with cefotaxime (100 mg/kg/
day in 3 daily doses, i.v.) plus clarithromycin (15 mg/kg/
day in two daily doses, orally) (control group) according 
to the guidelines for the treatment of pediatric CAP pre-
pared by the Italian Society of Pediatrics [27] or the same 
antibiotics plus PDT (800  mg/day in two daily doses, 
orally) (PDT group). In both groups, cefotaxime was 
administered for 4  days and then followed by amoxicil-
lin-clavulanate (80 mg/kg/day in 3 daily doses, orally, for 
6 days), and clarithromycin was administered at the same 
dosage for 14 days; in the PDT arm, PDT was given at the 
same dosage for 14 days.
Blood samples for the evaluation of immunological 
parameters were drawn at T3 and T5 (i.e., 3 and 5 days 
after the initiation of therapy) as well as at T21 (i.e., 
7  days after the therapy ended). All of the information 
was registered in an electronic database.
Immunological analyses
Whole blood was collected by venipuncture in Vacu-
tainer tubes containing ethylenediaminetetraacetic acid 
(EDTA, BD Vacutainer, San Diego, CA, USA). PBMCs 
were separated from whole blood by density gradient 
centrifugation on Ficoll (Cedarlane Laboratories Limited, 
Hornby, Ontario, Canada) after centrifugation for 25 min 
at 2300  rpm. PBMC layers were carefully removed and 
washed twice in phosphate-buffered saline (PBS, PBI, 
Milan, Italy), and cell counts and viability were deter-
mined with an automated cell counter (ADAM-MC, Dig-
ital Bio, NanoEnTek Inc., Korea).
PBMCs were incubated for 3 or 24 h for mRNA or protein 
analyses, respectively, in the following conditions: without 
any stimulus, in the presence of a mixture of 8 pneumococ-
cal polysaccharides (10  μg/mL) (ATCC® Pneumococcal 
polysaccharide type 23, 4, 14, 9, 57, 6A, 3, 5, LGC Standards, 
Milan, Italy) or in the presence of lipopolysaccharide (LPS, 
Sigma-Aldrich, St. Louis, MO, USA) (2 μg/mL). Anti-CD28 
antibody (R&D Systems, Minneapolis, MN, USA) was 
added during incubation (2 μg/mL) to facilitate costimula-
tion. For cytokine analyses, 10 μg/mL brefeldin A (Sigma-
Aldrich, St. Louis, MO, USA) was added to the cultures 
after 3 h of stimulation to block protein secretion.
After 18 h of stimulation, PBMCs were washed, resus-
pended in PBS (PBI, Milan, Italy), and split into different 
flow cytometry tubes. Antigen presenting cells (APCs) 
were evaluated by flow cytometric analyses. PBMCs were 
stained for 15  min at room temperature for anti-CD14, 
TLR4, TLR2, CD11c, HLA-DRII, CD80 and CD86.
Intracellular cytokine secretion was assessed with 
monoclonal antibodies (mAbs) specific for tumor necro-
sis factor (TNF)-α and interleukin (IL)-12. After 45 min 
of incubation at 4 °C in the dark, cells were washed and 
fixed in 1 % paraformaldehyde in PBS.
The following monoclonal antibodies (mAbs) were 
used: anti-human CD11c (mouse IgG1 isotype) phyco-
erythrin-Cy7 (PECy7), anti-human CD14 (mouse IgG1 
isotype) R-phycoerythrin-cyanine 5 (PECy5), anti-human 
HLA-DRII (mouse IgG1 isotype) R-phycoerythrin-cya-
nine 5 (PECy5), anti-human CD86 (mouse IgG1 isotype) 
phycoerythrin (PE), anti-human TLR2 (mouse IgG2a 
isotype) and anti-human CD80 all coupled to fluores-
cein isohiocyanate (FITC) (Beckman-Coulter, Milano, 
Italia). The mAbs used for detection via intracellular 
staining were anti-human TNF-α (mouse IgG1 isotype) 
phycoerythrin (PE) (R&D Systems, Minneapolis, MN, 
USA) and anti-human IL-12 (mouse IgG1 isotype) fluo-
rescein isohiocyanate (FITC) (BD Biosciences, San Diego, 
CA).
Cytometric analyses of phenotypes and cytokine secre-
tion were performed using an FC500 flow cytometer 
(Beckman-Coulter, Milano, Italia) equipped with a dou-
ble 15-mW argon ion laser with a wavelength of between 
456 and 488 nm interfaced with an Intercorp computer. 
Green fluorescence from FITC (FL1) was collected 
through a 525  nm band-pass filter; orange-red fluores-
cence from PE (FL2) was collected through a 575  nm 
band-pass filter; Texas red fluorescence from ECD (FL3) 
was collected through a 613  nm band-pass filter; red 
fluorescence from PECy5 (FL4) was collected through a 
670 nm band-pass filter; far red fluorescence from PECy7 
(FL5) was collected through a 770  nm band-pass filter. 
Data were collected using linear amplifiers for forward 
and side scatter and logarithmic amplifiers for FL1, FL2, 
FL3, FL4 and FL5. Samples were first run using isotype 
controls or single fluorochrome-stained preparations 
for color compensation. For each analysis, 20,000 events 
were acquired and gated for CD14 and CD11c expression 
and SSC properties.
After 3 h of pneumococcal polysaccharide stimulation, 
RNA was extracted from PBMCs by the acid guanidin-
ium thiocyanate-phenol–chloroform method. The RNA 
was dissolved in RNase-free water and purified from 
genomic DNA with RNase-free DNase (RQ1 DNase, 
Promega, Madison, Wisconsin, USA). One microgram of 
RNA was reverse transcribed into first-strand cDNA in a 
20-µL final volume containing 1 µM random hexanucleo-
tide primers, 1 µM oligo dT and 200 U Moloney murine 
leukemia virus reverse transcriptase (Clontech, Palo Alto, 
California, USA).
The antibacterial response signaling pathway was ana-
lyzed using a real-time polymerase chain reaction PCR 
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Table 1 Main demographic, clinical and laboratory characteristics at baseline in 20 children hospitalized for community-
acquired pneumonia according to the use of pidotimod plus antibiotics or antibiotics only
Characteristic All children (n = 20) Pidotimod + antibiotics (n = 10) Antibiotics only (n = 10) p-value
Demographics
 Age (years)
  Mean (SD) 4.6 (1.9) 4.4 (2.0) 4.7 (1.8) 0.70a
 Sex (%)
  Male 14 (70) 7 (70) 7 (70)
  Female 6 (30) 3 (30) 3 (30) 1
 Ethnicity (%)
  Caucasian 17 (85) 8 (80) 9 (90)
  Non-caucasian 3 (15) 2 (20) 1 (10) 0.99b
 Parental smoking habitb (%)
  Both non-smokers (%) 13 (65) 6 (60) 7 (70)
  At least one smoker (%) 7 (35) 4 (40) 3 (30) 0.99b
 Exclusive breastfeeding ≥3 monthsc
  Yes (%) 11 (58) 4 (40) 7 (78)
  No (%) 8 (42) 6 (60) 2 (22) 0.17b
 Diagnosis of allergy (%)
  Yes 18 (90) 9 (90) 9 (90)
  No 2 (10) 1 (10) 1 (10) 1
 Respiratory infections in the previous 6 months (%)
  At least one 13 (65) 5 (50) 8 (80)
  None 7 (35) 5 (50) 2 (20) 0.35b
 Use of antibiotics for respiratory infection in the previous 6 months (%)
  Yes 4(20) 2(20) 2(20)
  No 16 (80) 8 (80) 8 (80) 1
Clinical characteristics
 Fever (≥37.8°)c (%)
  Yes 8 (42) 5 (56) 3 (30) 0.37b
  No 11 (58) 4 (44) 7 (70)
 Coughc (%)
  Yes 18 (95) 8 (89) 10 (100)
  No 1 (5) 1 (11) 0 (0) 0.47b
 Dyspneac (%)
  Yes 4 (21) 2 (22) 2 (20)
  No 15 (79) 7 (78) 8 (80) 0.99b
 Rhonchi (%)
  Yes 1 (5) 1 (10) 0 (0)
  No 19 (95) 9 (90) 10 (100) 0.99b
 Rales (%)
  Yes 16 (80) 7 (70) 9 (90)
  No 4 (20) 3 (30) 1 (10) 0.58b
 Wheezes (%)
  Yes 4 (20) 3 (30) 1 (10)
  No 16 (80) 7 (70) 9 (90) 0.58b
 SpO2 <92 % (%)
  Yes 7 (35) 2 (20) 5 (50)
  No 13 (65) 8 (80) 5 (50) 0.35b
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array including a set of optimized real-time PCR primer 
assays on 96-well plates (SABiosciences Corporation, 
Frederick, MD, USA). This approach permits the moni-
toring of the mRNA expression of 84 genes involved in 
the innate immune response to bacteria plus five house-
keeping genes. The procedures were carried out accord-
ing to the manufacturer’s suggestions. Experiments were 
run on samples from all the subjects included in the 
study pooled into two groups: PDT and control. Thus, 
the results represent the mean values of the different 
targets analyzed in the PDT and control subjects. The 
results were analyzed with SABiosciences online soft-
ware, calculated relative to the housekeeping genes and 
expressed as ΔΔCt. Only targets that exhibited at least a 
2-fold modulation were considered significant.
Statistical analysis
In the tables displaying the main and clinical character-
istics at baseline, continuous variables are presented as 
mean values and standard deviations (SDs) and were ana-
lyzed using a non-parametric Wilcoxon-Mann–Whitney 
test. Categorical variables are presented as numbers and 
percentages and were analyzed by the Fisher’s exact test. 
All the tests were two-sided, and a p value <0.05 was con-
sidered statistically significant.
For the immunological data, p values for the differ-
ences between the PDT and control groups at each time 
point (i.e., day 3, day 5 and day 21) were estimated via 
two-tailed Wilcoxon-Mann–Whitney tests. The p val-
ues for the differences between the PDT and control 
groups across time were estimated via a 2-way ANOVA 
on ranks. We also performed a test to evaluate the linear 
trend between the PDT and control groups across time 
using a 2-way ANOVA on ranks with a first degree poly-
nomial contrast for time. The data were analyzed using 
SAS version 9.1 statistical software (SAS Institute, Cary, 
NC, USA).
Results
Study population
Table  1 shows the demographic and clinical character-
istics of the study patients. A total of 20 children (mean 
age ± SD, 4.6 ± 1.9 years; 14 [70.0 %] males) hospitalized 
for CAP were enrolled. Ten received PDT plus standard 
antibiotic therapy and 10 received standard antibiotics 
only. The two groups were comparable for all the studied 
demographic and health history variables, including eth-
nicity, parental smoking habits, exclusive breastfeeding 
for ≥3 months, previous diagnosis of allergic disease, and 
respiratory infection or antibiotic treatment in the previ-
ous 6  months. Clinical and laboratory characteristics of 
the study children were also similar between the groups. 
In particular, no significant differences at baseline were 
found between children randomized to receive PDT plus 
antibiotics and those who received antibiotics only with 
regard to the prevalence of fever, cough, or dyspnea, or 
with regard to thoracic findings, WBC counts, or CRP 
and PCT levels.
PDT induces dendritic cell maturation and activation
The data regarding dendritic cell (DC) maturation 
according to treatment arm are reported in Fig.  1. DCs 
were characterized by analyzing the expression of surface 
markers associated with cell activation and maturation, 
MHC class II molecules (HLA-DRII) and costimula-
tory molecules (CD80, CD86). Cytokine production was 
assessed upon PBMC stimulation in  vitro with pneu-
mococcal polysaccharides or LPS. The surface and mor-
phological activation status of DCs was comparable at 
baseline in both groups of subjects. The percentage of 
CD11c+ cells expressing either HLA-DRII (Fig. 1a), CD80 
(Fig. 1b) or CD86 (Fig. 1c) significantly increased in the 
PDT group compared to the controls 5 and 21 days after 
therapy initiation. The difference in CD80 expression was 
also significant across time (p for trend = 0.041). Similar 
CRP C reactive protein, PCT procalcitonin, SD standard deviation
a p value from Wilcoxon-Mann–Whitney test
b p value from Fisher’s Exact Test
c The sum does not add up to the total because of missing values
Table 1 continued
Characteristic All children (n = 20) Pidotimod + antibiotics (n = 10) Antibiotics only (n = 10) p-value
Laboratory results
 White blood cell count (cells/µL)
  Mean (SD) 13,154 (6512) 13,176 (6708) 13,132 (6672) 0.97a
  CRP (mg/L)
 Mean (SD) 5.95 (6.58) 5.82 (5.02) 6.07 (4.25) 0.82a
  PCT (ng/mL)
  Mean (SD) 0.40 (0.84) 0.42 (0.89) 0.38 (0.84) 0.96a
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results were obtained upon stimulation with LPS (data 
not shown).
Analyses of cytokine release from DCs revealed that 
the percentage of CD11c+ cells secreting TNF-α or 
IL-12 became higher in the PDT group compared to 
the control group at days 5 and 21, with a significant p 
for trend for both cytokines across time (p = 0.007, and 
p  =  0.030, respectively) (Fig.  2a, b). The percentage of 
CD11c+ cells secreting TNF-α or IL-12 was higher at all 
times, although not significantly, in the PDT group than 
Fig. 1 Percentages of pneumococcal-stimulated positive dendritic 
cells (CD11c+) expressing HLA-DRII (a), CD86 (b) and CD80 (c) mol-
ecules are shown at baseline and in response to therapy in children 
with community-acquired pneumonia (CAP) treated with antibiotics 
plus pidotimod and in controls treated with antibiotics only. For each 
analysis, 30,000 events were acquired and gated on CD11c expression 
and side scatter properties. Mean values + SD and statistically signifi-
cant differences are indicated
Fig. 2 Percentages of pneumococcal-stimulated dendritic cells 
(CD11c+) secreting TNF-α (a) and IL-12 (b) are shown at baseline and 
in response to therapy in children with community-acquired pneu-
monia (CAP) treated with antibiotics plus pidotimod and in controls 
treated with antibiotics only. The percentage of TNF-α/IL-12 secreting 
CD11c+ cells was higher in the therapy group than in the controls, 
although significant differences were observed only at T5 and T21 (c). 
For each analysis, 30,000 events were acquired and gated on CD11c 
expression and side scatter properties. Mean values + SD and statisti-
cally significant differences are indicated
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in the controls (Fig. 2c). Similar data were observed when 
cells were stimulated with LPS (data not shown).
PDT induces monocyte maturation and activation
Activation of monocytes (CD14+ cells) via TLRs and 
secretion of pro-inflammatory mediators was also eval-
uated after stimulation of PBMCs with pneumococ-
cal polysaccharides or LPS. As shown in Fig.  3a, TLR2 
expression on CD14  +  cells was significantly higher in 
the PDT group compared with the control group 5 and 
21 days after treatment initiation, with a significant p for 
trend for the comparison across time between treatment 
groups (p  =  0.023). Peak inflammatory responses were 
detected 5 to 21  days after therapy administration with 
the strongest effect observed in either TNF-α-, IL-12- or 
TNF-α/IL-12-secreting CD14 +  cells in the PDT group 
compared with the control subjects (Fig. 3b–d).
PDT upregulates antibacterial responses
Figure 4 summarizes gene expression related to the anti-
bacterial response signaling pathway (Panel a). Follow-
ing pneumococcal polysaccharide stimulation, mRNA 
expression of antimicrobial peptides reached a peak of 
expression at day 5 with a subsequent decrease at day 21. 
The results demonstrate the same trend in both groups 
of patients, but the increases were more pronounced in 
the PDT-treated individuals. Likewise, an upregulation 
of inflammatory response genes was also observed in the 
PDT-treated group in comparison with the control group 
(Panel b).
Discussion
This is the first study in which the influence of PDT on 
immune system function during an acute infectious dis-
ease was evaluated. Our data indicate that PDT admin-
istration in addition to standard antibiotic therapy in 
children with CAP may significantly increase the natural 
immune system response to an infectious stimulus via a 
direct influence on DC maturation and function, TLR2 
expression in monocytes, antimicrobial peptide secretion 
and upregulation of genes involved in the inflammatory 
response. The positive effect was observable after only a 
few days of PDT administration and remained evident for 
several days after the drug treatment ended.
DCs are cells of the mononuclear phagocyte system 
that play a critical role in the regulation of the adaptive 
Fig. 3 TLR2 expression on monocytes (CD14+) (a) and percentages of CD14 + cells expressing TNF-α (b), IL-12 (c) or TNF-α/IL-12 (d) are shown at 
baseline and in response to therapy in children with community-acquired pneumonia (CAP) treated with antibiotics plus pidotimod and in controls 
treated with antibiotics only. For each analysis, 30,000 events were acquired and gated on CD11c expression and side scatter properties. Mean 
values + SD and statistically significant differences are indicated
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immune response [28]. At steady state, DCs are described 
as immature, a phenotype characterized by low surface 
expression of MHC class II molecules and co-stimulatory 
molecules such as CD80 and CD86. In response to activa-
tion by infection, DCs undergo a program of maturation 
that leads to the acquisition of a number of fundamental 
properties including antigen processing and presenta-
tion, migration and T cell co-stimulation. In this context, 
upregulation of co-stimulatory molecules and HLA-DRII 
antigens is evidenced together with a significant produc-
tion of pro-inflammatory cytokines, such as IL-12 and 
TNF-α, which play an important role in the polariza-
tion of T helper cell subsets toward a Th1 profile during 
priming by DCs and thus experience the functional con-
sequences of DC activation [29].
In this study, it was found that PDT administration 
results in DC activation and maturation as evidenced 
by the increased number of DCs expressing costimula-
tory molecules such as CD86 and CD80. Stimulation of 
the immune system induced by PDT is also evidenced by 
the increase in the number of cells that, particularly after 
exposure to bacterial components, were found to be able 
to produce IL-12 as well as TNF-α. Similar results were 
observed regarding TLR expression and proinflammatory 
cytokine production in monocytes. In particular, TLR2 
plays a major role in promoting protective immunity 
Fig. 4 Antibacterial response signaling pathway: antimicrobial peptides (a) and genes involved in the inflammatory response (b) at baseline as well 
as at days 3, 5 and 21 in children with community-acquired pneumonia (CAP) treated with antibiotics plus pidotimod and in controls treated with 
antibiotics only
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against respiratory pathogens [30], and its upregulation 
could reduce susceptibility to further respiratory infec-
tions. In contrast in PDT-treated children, the increased 
expression of antimicrobial peptides (e.g., CAMP, LCN2, 
LTF and MPO) and genes involved in cell chemotaxis, the 
upregulation of the inflammatory response and increased 
apoptosis [31–33], (e.g., CCL3, CXCL1, CXCL2, IL-18, 
IL-1b, IL-6, IL-8, NFkB1, and NLRP3) suggest that PDT 
administration might significantly increase the activity of 
the immune system for a long period of time, thus reduc-
ing the risk of early recurrences during CAP in children.
Our study was a pilot project with an immunologi-
cal primary endpoint; to observe clinically significant 
differences during the treatment of an acute pediat-
ric infection, a larger sample size is needed. Our results 
encourage further studies on infected mice in order to 
confirm these immunological findings and their clini-
cal relevance as well as on larger populations using PDT 
in addition to the current standard of care for the acute 
treatment of pediatric CAP in order to evaluate whether 
the observed biological effects are associated with dif-
ferences in the clinical outcome. In addition, further 
research should evaluate how long this positive immune 
effect persists and whether it is also observed in compli-
cated CAP cases and other pediatric infectious diseases.
Conclusions
This study demonstrates for the first time that PDT 
administration together with standard antibiotic therapy 
is associated with a favorable persistent immunomodula-
tory effect in children with CAP, suggesting that it could 
reduce the risk of early recurrences.
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